SPATA31A7

Across TCGA pan-cancer cohorts, SPATA31A7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPATA31A7 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SPATA31A7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31A7 expression acts as an unfavorable survival marker.

BRCA, LUAD, and LGG are the cancer types where SPATA31A7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.112	0.578	.001	24	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	18	view →
LGG	OS	Median	All	0.182	0.909	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.226	0.686	.013	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPATA31A7–BRCA (OS)

Open the BRCA breakdown →